In 970 patients with refractory metastatic colorectal cancer in Japan, a 14-day trifluridine-tipiracil plus bevacizumab schedule was non-inferior to the 28-day schedule for overall survival (median 11·3 vs 10·3 months; HR 0·93), with less grade ≥3 neutropenia (13% vs 39%).
RCTn = 970
Sakakida et al. 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan